<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859105</url>
  </required_header>
  <id_info>
    <org_study_id>IMIQ-TOCR-01RB01-CE</org_study_id>
    <nct_id>NCT00859105</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Therapeutic Equivalence Study of Three Imiquimod Cream 5% Treatments for Patients With Actinic Keratosis</brief_title>
  <official_title>A Multicenter, Double-Blind, Vehical-Controlled Study Comparing Imiquimod Cream, 5% (Apotex Inc.) to Aldara™ Cream, 5%(3M Pharmaceutials, U.S.) and Aldara™ Cream, 5%(3M Pharmaceuticals, Canada) in the Treatments of Actinic Keratosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apotex Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apotex Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor),
      Placebo Control, Parallel Assignment, Bio-equivalence Study
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objectives are to establish the therapeutic equivalence of imiquimod cream 5%, manufactured by Apotex Inc. and two Aldara (imiquimod) creams, manufactured by 3M (US &amp; Canada) , and to show superiority over vehicle in the treatment of AK.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective is to compare the safety profiles of the three creams.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">497</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Imiquimod 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Manufactured by Apotex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adara 5 % Cream US</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manufactured by 3M, US.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adara 5% Cream Canada</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Manufactured by 3M, Canada</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Manufactured by Apotex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5%: manufactured by Apotex</intervention_name>
    <description>Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks</description>
    <arm_group_label>Imiquimod 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adara 5% Cream US</intervention_name>
    <description>Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks</description>
    <arm_group_label>Adara 5 % Cream US</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adara 5% Cream Canada</intervention_name>
    <description>Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.</description>
    <arm_group_label>Adara 5% Cream Canada</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod Vehicle</intervention_name>
    <description>Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have 4 to 8 clinically diagnosed, non-hyperkeratotic, non-hypertrophic
             AK lesions within a 25 cm2 contiguous treatment area on either the face or balding
             scalp

          -  Women either must be 1 year post-menopausal, surgically sterile, or agree to use a
             medically accepted form or birth control

          -  Free of any systemic or dermatological disorder

          -  Any skin type or race, providing the skin pigmentation will allow discernment of
             erythema

        Exclusion Criteria:

          -  Basal cell or squamous cell carcinoma, or other possible confounding skin conditions
             (on face and scalp)

          -  History of cutaneous hyperreactivity or facial irritation to topical products

          -  Engaging in activities involving excessive or prolonged exposure to sunlight

          -  Receiving systemic cancer chemotherapy, psoralen plus UVA therapy, UVB therapy, laser
             abrasion, dermabrasion, glycolic acids, or chemical peels 6 months prior to study
             entry

          -  Currently using or have used systemic steroids 2 months prior to study

          -  Currently using or have used on the treatment area over-the-counter retinol products,
             corticosteroids, cryosurgery, curettage, 5-fluorouracil, or other topical actinic
             keratosis treatments 28 days prior to randomization

          -  Pregnant or nursing mothers

          -  History of allergy or sensitivity to imiquimod or related compounds or other
             components of the formulation

          -  Taking immunosuppressant medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Brooks</last_name>
    <role>Study Director</role>
    <affiliation>Apotex Inc.</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>March 9, 2009</last_update_submitted>
  <last_update_submitted_qc>March 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Bernice Tao</name_title>
    <organization>Director, Regulatory Affairs U.S.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

